FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890887107> ?p ?o ?g. }

• W2890887107 endingPage "e0203312" @default.
• W2890887107 startingPage "e0203312" @default.
• W2890887107 abstract "The management of patients with chronic hepatitis B infection is quite complex because it requires an in-depth knowledge of the natural history of the disease. This study was aimed at characterizing HBV infected patients in order to determine the phase of the infection and identify the proportion eligible for treatment using 3 different guidelines.HBV chronically infected patients (negative for HIV and HCV) were enrolled and the following tests were done for them: ALT, AST, HBV viral load, HBV serologic panel and Full blood count. APRI score was calculated for all patients. These patients were classified into immunotolerant, immune clearance, immune control and immune escape phases of the infection. The WHO and the 2018 AASLD criteria was also used to identify those who need treatment. Patients were clinically examined for signs and symptoms. Questionnaire was administered to all participants to ascertain their treatment status. Statistical analysis was done using SPSS version 21.A total of 283 participants (101 females and 182 males) with a mean age of 31.3±8.5 were enrolled. Fifty-two (18.4%) were eligible for treatment (Immune clearance and immune escape phases) and they recorded a significantly higher mean APRI score (0.71±0.51) as compared to those in the immune control and immune tolerant phase (0.43±0.20). Based on WHO and AASLD criteria, 12(4.2%) and 15 (5.3%) were eligible for treatment respectively and these were all subsets of the 52 cases mentioned above. Six (2.1%) and 29 (10.2%) of those identified under the immune control phase were on tenofovir and traditional medication respectively.Considering treatment for patients in the immune clearance and immune escape phases of the infection can be a reliable strategy to implement in our setting as this may probably tie with considerations from other treatment guidelines. Fifty-two (18.4%) patients were eligible for treatment and none of them were among the 2.1% of patients put on Tenofovir based treatment. This calls for the need for more trained health experts to periodically assess patients, implement an adequate treatment guideline and place the right patients on treatment in Cameroon." @default.
• W2890887107 created "2018-09-27" @default.
• W2890887107 creator A5003462915 @default.
• W2890887107 creator A5003618551 @default.
• W2890887107 creator A5007990114 @default.
• W2890887107 creator A5013271954 @default.
• W2890887107 creator A5017621378 @default.
• W2890887107 creator A5037771222 @default.
• W2890887107 creator A5042491535 @default.
• W2890887107 creator A5053751135 @default.
• W2890887107 creator A5073435282 @default.
• W2890887107 creator A5085089368 @default.
• W2890887107 creator A5090531126 @default.
• W2890887107 date "2018-09-05" @default.
• W2890887107 modified "2023-09-26" @default.
• W2890887107 title "Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon" @default.
• W2890887107 cites W1507129267 @default.
• W2890887107 cites W1601582874 @default.
• W2890887107 cites W1799522345 @default.
• W2890887107 cites W1980612719 @default.
• W2890887107 cites W1997865776 @default.
• W2890887107 cites W2009474584 @default.
• W2890887107 cites W2021031772 @default.
• W2890887107 cites W2023367273 @default.
• W2890887107 cites W2032627193 @default.
• W2890887107 cites W2036787317 @default.
• W2890887107 cites W2057703647 @default.
• W2890887107 cites W2067109440 @default.
• W2890887107 cites W2070454678 @default.
• W2890887107 cites W2079950156 @default.
• W2890887107 cites W2083045518 @default.
• W2890887107 cites W2091895832 @default.
• W2890887107 cites W2097018453 @default.
• W2890887107 cites W2103242107 @default.
• W2890887107 cites W2141460271 @default.
• W2890887107 cites W2142788779 @default.
• W2890887107 cites W2147283902 @default.
• W2890887107 cites W2148898236 @default.
• W2890887107 cites W2162343359 @default.
• W2890887107 cites W2173698250 @default.
• W2890887107 cites W2174723704 @default.
• W2890887107 cites W2301284828 @default.
• W2890887107 cites W2475385134 @default.
• W2890887107 cites W2557688427 @default.
• W2890887107 cites W2588286931 @default.
• W2890887107 cites W2602147605 @default.
• W2890887107 cites W2605785536 @default.
• W2890887107 cites W2609179041 @default.
• W2890887107 cites W2610211724 @default.
• W2890887107 cites W2735007714 @default.
• W2890887107 cites W2791839818 @default.
• W2890887107 cites W89614756 @default.
• W2890887107 doi "https://doi.org/10.1371/journal.pone.0203312" @default.
• W2890887107 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6124766" @default.
• W2890887107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30183765" @default.
• W2890887107 hasPublicationYear "2018" @default.
• W2890887107 type Work @default.
• W2890887107 sameAs 2890887107 @default.
• W2890887107 citedByCount "9" @default.
• W2890887107 countsByYear W28908871072019 @default.
• W2890887107 countsByYear W28908871072020 @default.
• W2890887107 countsByYear W28908871072021 @default.
• W2890887107 countsByYear W28908871072022 @default.
• W2890887107 crossrefType "journal-article" @default.
• W2890887107 hasAuthorship W2890887107A5003462915 @default.
• W2890887107 hasAuthorship W2890887107A5003618551 @default.
• W2890887107 hasAuthorship W2890887107A5007990114 @default.
• W2890887107 hasAuthorship W2890887107A5013271954 @default.
• W2890887107 hasAuthorship W2890887107A5017621378 @default.
• W2890887107 hasAuthorship W2890887107A5037771222 @default.
• W2890887107 hasAuthorship W2890887107A5042491535 @default.
• W2890887107 hasAuthorship W2890887107A5053751135 @default.
• W2890887107 hasAuthorship W2890887107A5073435282 @default.
• W2890887107 hasAuthorship W2890887107A5085089368 @default.
• W2890887107 hasAuthorship W2890887107A5090531126 @default.
• W2890887107 hasBestOaLocation W28908871071 @default.
• W2890887107 hasConcept C126322002 @default.
• W2890887107 hasConcept C142462285 @default.
• W2890887107 hasConcept C159654299 @default.
• W2890887107 hasConcept C203014093 @default.
• W2890887107 hasConcept C2522874641 @default.
• W2890887107 hasConcept C2777382497 @default.
• W2890887107 hasConcept C2780593183 @default.
• W2890887107 hasConcept C3013748606 @default.
• W2890887107 hasConcept C45189115 @default.
• W2890887107 hasConcept C71924100 @default.
• W2890887107 hasConcept C8891405 @default.
• W2890887107 hasConcept C90924648 @default.
• W2890887107 hasConceptScore W2890887107C126322002 @default.
• W2890887107 hasConceptScore W2890887107C142462285 @default.
• W2890887107 hasConceptScore W2890887107C159654299 @default.
• W2890887107 hasConceptScore W2890887107C203014093 @default.
• W2890887107 hasConceptScore W2890887107C2522874641 @default.
• W2890887107 hasConceptScore W2890887107C2777382497 @default.
• W2890887107 hasConceptScore W2890887107C2780593183 @default.
• W2890887107 hasConceptScore W2890887107C3013748606 @default.
• W2890887107 hasConceptScore W2890887107C45189115 @default.
• W2890887107 hasConceptScore W2890887107C71924100 @default.

• next